



RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Saxon et al.

) Group Art Unit 1644

Appl. No. : 09/847,208

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

Filed : May 1, 2001

**For : FUSION MOLECULES AND  
TREATMENT OF IgE-  
MEDIATED ALLERGIC  
DISEASES**

July 27, 2001

(Date)

Ginger R. Dreger, Reg. No. 33,055

Examiner : Huynh, P.

## AMENDMENT AND RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In reply to the Office Action mailed on June 28, 2001 (Paper No. 3) in connection with the above-identified patent application, setting a shortened statutory period of one month, please amend this application as follows.

In the Claims:

Please cancel claims 7-21, 28, 31-39, and 54-72, without prejudice.

**Please amend claim 1 to read as follows:**

1. (Amended) An isolated fusion molecule comprising a first polypeptide sequence, other than an antibody variable region, capable of specific binding to a native IgG inhibitory receptor comprising an immune receptor tyrosine-based inhibitory motif (ITIM), expressed on mast cells, basophils or B cells, functionally connected to a second polypeptide sequence, other than an antibody variable region, capable of specific binding directly to a native IgE receptor (FcεR).